We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is ...

Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks ...

Humacyte is cutting about a quarter of its workforce as it revamps its commercial strategy. Durham biotech's breakthrough ...

Humacyte, Inc. (HUMA) closed at $0.70 in the latest trading session, marking a -1.14% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.8%. Meanwhile, the Dow ...

Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech ...

Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were ...

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, ...

Humacyte (NASDAQ:HUMA) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete ...

Humacyte reported Q1 2026 financial results showing sales increased to $500,000 in Q1 2025, but the biotech company is ...

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago. These figures are ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...